About
Pipeline
For patients & physicians
Investors
Contact us
About
About BerGenBio
Management Team
Board of Directors
Scientific Advisory Board
Partners
Pipeline
Pipeline overview
BEMCENTINIB | NSCLC
BEMCENTINIB | SRI
TILVESTAMAB (BGB149)
Publications
For patients & physicians
Investors
Share Information and Policies
Share Data
Largest Shareholders
Stock Exchange Notices
Analyst Coverage
News
Financial Reports
Presentations
Financial Calendar
Corporate Governance
General Meetings
Environmental social and governance - ESG
Investor Relations
Rights Issue 2023
Warrants
Contact us
Developing breakthrough AXL therapeutics to improve patients' lives
D
e
v
e
l
o
p
i
n
g
b
r
e
a
k
t
h
r
o
u
g
h
A
X
L
t
h
e
r
a
p
e
u
t
i
c
s
t
o
i
m
p
r
o
v
e
p
a
t
i
e
n
t
s
'
l
i
v
e
s
Learn About Us
Latest news
Read more
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
Recent News
26th June 2024
BerGenBio ASA: Grant of share options
Read more
3rd June 2024
BerGenBio ASA – Registration of reverse share split
Read more
30th May 2024
BerGenBio ASA - Ex. reverse share split and change of ISIN today
Read more
29th May 2024
BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development
Read more
28th May 2024
BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®
Read more
28th May 2024
BerGenBio ASA - Key information relating to the reverse share split and change of ISIN
Read more
28th May 2024
BerGenBio ASA: New share capital registered
Read more
23rd May 2024
BerGenBio ASA – Minutes from the annual general meeting 2024
Read more
22nd May 2024
BerGenBio ASA: Invitation to first quarter 2024 results webcast
Read more
All news
